NEs can bind to circulating tumor cells or inflammatory endothelial cells through ligand receptor interactions, such as CD44 and L-selectin, LFA-1 and ICAM-1, and β 1 integrin and VCAM-1 [137]. This evidence concerns the gene CD44 and neoplasm.